These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 35558088)

  • 1. Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions.
    Sowa AS; Haas E; Hübener-Schmid J; Lorentz A
    Front Immunol; 2022; 13():870966. PubMed ID: 35558088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.
    Switonski PM; Szlachcic WJ; Krzyzosiak WJ; Figiel M
    Neurobiol Dis; 2015 Jan; 73():174-88. PubMed ID: 25301414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Druggable genome screen identifies new regulators of the abundance and toxicity of ATXN3, the Spinocerebellar Ataxia type 3 disease protein.
    Ashraf NS; Sutton JR; Yang Y; Ranxhi B; Libohova K; Shaw ED; Barget AJ; Todi SV; Paulson HL; Costa MDC
    Neurobiol Dis; 2020 Apr; 137():104697. PubMed ID: 31783119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of spinocerebellar ataxia type 3 mouse models identifies early gain-of-function, cell-autonomous transcriptional changes in oligodendrocytes.
    Ramani B; Panwar B; Moore LR; Wang B; Huang R; Guan Y; Paulson HL
    Hum Mol Genet; 2017 Sep; 26(17):3362-3374. PubMed ID: 28854700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy in Spinocerebellar Ataxia Type 3: From Pathogenesis to Therapeutics.
    Paulino R; Nóbrega C
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered Levels of Proteins and Phosphoproteins, in the Absence of Early Causative Transcriptional Changes, Shape the Molecular Pathogenesis in the Brain of Young Presymptomatic Ki91 SCA3/MJD Mouse.
    Wiatr K; Piasecki P; Marczak Ł; Wojciechowski P; Kurkowiak M; Płoski R; Rydzanicz M; Handschuh L; Jungverdorben J; Brüstle O; Figlerowicz M; Figiel M
    Mol Neurobiol; 2019 Dec; 56(12):8168-8202. PubMed ID: 31201651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
    Li X; Liu H; Fischhaber PL; Tang TS
    Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
    Dantuma NP; Herzog LK
    Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant Ataxin-3-Containing Aggregates (MATAGGs) in Spinocerebellar Ataxia Type 3: Dynamics of the Disorder.
    Raj K; Akundi RS
    Mol Neurobiol; 2021 Jul; 58(7):3095-3118. PubMed ID: 33629274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The deubiquitinase function of ataxin-3 and its role in the pathogenesis of Machado-Joseph disease and other diseases.
    Potapenko A; Davidson JM; Lee A; Laird AS
    Biochem J; 2024 Mar; 481(6):461-480. PubMed ID: 38497605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Karyopherin α-3 is a key protein in the pathogenesis of spinocerebellar ataxia type 3 controlling the nuclear localization of ataxin-3.
    Sowa AS; Martin E; Martins IM; Schmidt J; Depping R; Weber JJ; Rother F; Hartmann E; Bader M; Riess O; Tricoire H; Schmidt T
    Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2624-E2633. PubMed ID: 29476013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of an induced pluripotent stem cell line from a patient with spinocerebellar ataxia type 3 (SCA3): HIHCNi002-A.
    Hayer SN; Schelling Y; Huebener-Schmid J; Weber JJ; Hauser S; Schöls L
    Stem Cell Res; 2018 Jul; 30():171-174. PubMed ID: 29936336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
    Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
    Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo assessment of riluzole as a potential therapeutic drug for spinocerebellar ataxia type 3.
    Schmidt J; Schmidt T; Golla M; Lehmann L; Weber JJ; Hübener-Schmid J; Riess O
    J Neurochem; 2016 Jul; 138(1):150-62. PubMed ID: 26990650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of PNKP by mutant ATXN3 triggers apoptosis by activating the DNA damage-response pathway in SCA3.
    Gao R; Liu Y; Silva-Fernandes A; Fang X; Paulucci-Holthauzen A; Chatterjee A; Zhang HL; Matsuura T; Choudhary S; Ashizawa T; Koeppen AH; Maciel P; Hazra TK; Sarkar PS
    PLoS Genet; 2015 Jan; 11(1):e1004834. PubMed ID: 25590633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel SCA3 Knock-in Mouse Model Mimics the Human SCA3 Disease Phenotype Including Neuropathological, Behavioral, and Transcriptional Abnormalities Especially in Oligodendrocytes.
    Haas E; Incebacak RD; Hentrich T; Huridou C; Schmidt T; Casadei N; Maringer Y; Bahl C; Zimmermann F; Mills JD; Aronica E; Riess O; Schulze-Hentrich JM; Hübener-Schmid J
    Mol Neurobiol; 2022 Jan; 59(1):495-522. PubMed ID: 34716557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodegenerative phosphoprotein signaling landscape in models of SCA3.
    Sowa AS; Popova TG; Harmuth T; Weber JJ; Pereira Sena P; Schmidt J; Hübener-Schmid J; Schmidt T
    Mol Brain; 2021 Mar; 14(1):57. PubMed ID: 33741019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Machado-Joseph disease/spinocerebellar ataxia type 3.
    Paulson H
    Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired Oligodendrocyte Maturation Is an Early Feature in SCA3 Disease Pathogenesis.
    Schuster KH; Zalon AJ; Zhang H; DiFranco DM; Stec NR; Haque Z; Blumenstein KG; Pierce AM; Guan Y; Paulson HL; McLoughlin HS
    J Neurosci; 2022 Feb; 42(8):1604-1617. PubMed ID: 35042771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3.
    Boy J; Schmidt T; Wolburg H; Mack A; Nuber S; Böttcher M; Schmitt I; Holzmann C; Zimmermann F; Servadio A; Riess O
    Hum Mol Genet; 2009 Nov; 18(22):4282-95. PubMed ID: 19666958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.